Source: Annual Congress 2002 - Asthma, COPD and management in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Ind, J. Haughney, D. Price, J. P. Rosen, J. Kennelly (London, Aberdeen, Luton, United Kingdom). Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose. Eur Respir J 2002; 20: Suppl. 38, 2450

Member's Comments

No comment yet.

Related content which might interest you: Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018 Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Managed adjustable dosing of budesonide/formoterol combination is similarly well tolerated to fixed dosing Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003 Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004 Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Budesonide/formoterol with an adjustable maintenance plan costs less, and is as effective as fixed dosing Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Benefits of adjustable versus fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003 Budesonide/formoterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004 Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002 A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003 Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006